These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1101 related articles for article (PubMed ID: 29856033)

  • 41. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hope for Huntington's disease patients: first clinical gene silencing study in progress].
    Rollnik JD
    Fortschr Neurol Psychiatr; 2017 Aug; 85(8):463-466. PubMed ID: 28841744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
    Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
    Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.
    Caron NS; Banos R; Aly AE; Xie Y; Ko S; Potluri N; Anderson C; Black HF; Anderson LM; Gordon B; Southwell AL; Hayden MR
    Neurobiol Dis; 2022 May; 166():105652. PubMed ID: 35143966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mesenchymal stem cells alleviate AQP-4-dependent glymphatic dysfunction and improve brain distribution of antisense oligonucleotides in BACHD mice.
    Wu TT; Su FJ; Feng YQ; Liu B; Li MY; Liang FY; Li G; Li XJ; Zhang Y; Cai ZQ; Pei Z
    Stem Cells; 2020 Feb; 38(2):218-230. PubMed ID: 31648394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts.
    Ciesiolka A; Stroynowska-Czerwinska A; Joachimiak P; Ciolak A; Kozlowska E; Michalak M; Dabrowska M; Olejniczak M; Raczynska KD; Zielinska D; Wozna-Wysocka M; Krzyzosiak WJ; Fiszer A
    Cell Mol Life Sci; 2021 Feb; 78(4):1577-1596. PubMed ID: 32696070
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.
    Skotte NH; Southwell AL; Østergaard ME; Carroll JB; Warby SC; Doty CN; Petoukhov E; Vaid K; Kordasiewicz H; Watt AT; Freier SM; Hung G; Seth PP; Bennett CF; Swayze EE; Hayden MR
    PLoS One; 2014; 9(9):e107434. PubMed ID: 25207939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.
    Keller CG; Shin Y; Monteys AM; Renaud N; Beibel M; Teider N; Peters T; Faller T; St-Cyr S; Knehr J; Roma G; Reyes A; Hild M; Lukashev D; Theil D; Dales N; Cha JH; Borowsky B; Dolmetsch R; Davidson BL; Sivasankaran R
    Nat Commun; 2022 Mar; 13(1):1150. PubMed ID: 35241644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).
    Khan E; Tawani A; Mishra SK; Verma AK; Upadhyay A; Kumar M; Sandhir R; Mishra A; Kumar A
    ACS Chem Biol; 2018 Jan; 13(1):180-188. PubMed ID: 29172480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
    Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
    Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Huntingtin Lowering Strategies.
    Marxreiter F; Stemick J; Kohl Z
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RNA toxicity induced by expanded CAG repeats in Huntington's disease.
    Martí E
    Brain Pathol; 2016 Nov; 26(6):779-786. PubMed ID: 27529325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meso scale discovery-based assays for the detection of aggregated huntingtin.
    Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
    PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
    Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
    J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Copper enhances aggregational toxicity of mutant huntingtin in a Drosophila model of Huntington's Disease.
    Lobato AG; Ortiz-Vega N; Zhu Y; Neupane D; Meier KK; Zhai RG
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166928. PubMed ID: 38660915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
    Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
    Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics.
    Fienko S; Landles C; Sathasivam K; McAteer SJ; Milton RE; Osborne GF; Smith EJ; Jones ST; Bondulich MK; Danby ECE; Phillips J; Taxy BA; Kordasiewicz HB; Bates GP
    Brain; 2022 Dec; 145(12):4409-4424. PubMed ID: 35793238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
    Chen M; Wolynes PG
    Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic Antisense Targeting of Huntingtin.
    Smith AV; Tabrizi SJ
    DNA Cell Biol; 2020 Feb; 39(2):154-158. PubMed ID: 31821021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.